Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/022892external-prioritypatent/WO2004008946A2/en
Application filed by Beth Israel Deaconess Medical Ct IncfiledCriticalBeth Israel Deaconess Medical Ct Inc
Publication of TNSN05015A1publicationCriticalpatent/TNSN05015A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
DISCLOSED HEREIN ARE METHODS FOR DIAGNOSTING PRE-ECLAMPSIA AND ECLAMPSIA. ALSO DISCLOSED HEREIN ARE METHODS FOR TREATING PRE-ECLAMPSIA AND ECLAMPSIA USING COMPOUNDS THAT INCREASE VEGF OR PIGF LEVELS OR COMPOUNDS THAT DECREASE sFLT-1 LEVELS. COMPOUNDS THAT INHIBIT THE BINDING OF VEGF OR PIGF TO SFltl - ARE ALSO DISCLOSED HEREIN FOR THE TREATMENT OF PRE-ECLAMPSIA OR ECLAMPSIA.
TNP2005000015A2002-07-192005-01-19Methods of diagnosing and treating pre-eclampsia or eclampsia
TNSN05015A1
(en)
Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism